# US 2021/0080458 A1 · Means and methods for determining risk of type-1 diabetes by serum protein biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0080458 A1
- Document ID: US20210080458A1
- Status: Published application
- Kind: A1
- Application number: 17/101,693
- Filed: 2020-11-23
- Published: 2021-03-18
- Earliest claimed: 2014-06-18
- Assignees: Turun Yliopisto
- Applicants: Turun Yliopisto
- Inventors: Robert Moulder; Santosh BHOSALE; David GOODLETT; Harri LÄHDESMÄKI; Olli SIMELL; Riitta LAHESMAA
- Web page: https://patentgrep.com/patent/US20210080458A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4713: Plasma globulins, lactoglobulin
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G01N 2333/76: Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N 2333/775: Apolipopeptides
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.

## Claims

### Claim 1

A method of determining an individual at risk of and/or progression towards Type 1 Diabetes (T1D), the method comprising:
a) determining a protein marker profile in a sample obtained from the individual, said profile comprising profilin-1 (PROF1) and filamin-A (FLNA),
b) comparing the determined protein marker profile of PROF1 and FLNA of the individual with that of a corresponding control profile of PROF1 and FLNA in a control sample from a control individual or a pool of control individuals,
c) responsive to the comparison, determining the risk of and/or progression towards T1D in the individual, wherein higher levels of PROF1 and FLNA in the sample obtained from the individual as compared to the levels of PROF1 and FLNA in the control sample indicates that the individual is at risk of and/or progression towards T1D, and
d) providing a treatment or dietary change to the individual to prevent T1D development.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the protein marker profile and control profile further comprise transgelin-2 (TAGL2), wherein a higher level of TAGL2 in the sample obtained from the individual as compared to the level of TAGL2 in the control sample indicates that the individual is at risk of and/or progression towards T1D.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the individual is determined at risk of and/or progressing towards T1D prior to seroconversion in the individual.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the individual has a Human Leukocyte Antigen-conferred (HLA-conferred) risk of T1D.

### Claim 5 (depends on 1)

The method according to claim 1, further comprising:
determining one or more protein markers selected from the group consisting of sex hormone-binding globulin (SHBG), adiponectin (ADIPO), thyroxine-binding globulin (THBG), apolipoprotein C-II (APOC2), insulin-like growth factor-binding protein 2 (IBP2), apolipoprotein C-I (APOC1), apolipoprotein C-III (APOC3), fetuin-B (FETUB), serum amyloid P-component (SAMP), clusterin (CLUS), C4b-binding protein alpha chain (C4BPA), C4b-binding protein beta chain (C4BPB), complement factor I (CFAI), inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), insulin-like growth factor-binding protein 3 (IBP3), Serum amyloid A-4 protein (SAA4), complement component C8 alpha chain (CO8A), complement Clq subcomponent subunit B (C1QB), hyaluronan-binding protein 2 (HABP2), complement component C8 gamma chain (CO8G), transforming growth factor-beta-induced protein ig-h3 (BGH3), ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2), poliovirus receptor (PVR), vinculin (VINC), N-acetylmuramoyl-L-alanine amidase (PGRP2), contactin-1 (CNTN1), L-lactate dehydrogenase B chain 46 (LDHB), extracellular superoxide dismutase [Cu—Zn] (SODE), apolipoprotein A-IV (APOA4), neural cell adhesion and molecule 1 (NCAM1), and
comparing the determined one or more protein markers with that of corresponding control markers,
wherein a lower level of SHBG, ADIPO, THBG, APOC2, APOC1, APOC3, BGH3, ENPP2, PVR, VINC, PGRP2, CNTN1, LDHB, SODE, APOA4, NCAM1, or IBP2 in the sample obtained from the individual as compared to the levels in the control sample indicates that the individual is at risk of and/or progression towards T1D, and
wherein a higher level of FETUB, SAMP, CLUS, C4BPA, C4BPB, CFAI, ITIH4, IBP3, SAA4, CO8A, C1QB, HABP2, or CO8G in the sample obtained from the individual as compared to the levels in the control sample indicates that the individual is at risk of and/or progression towards T1D.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said a)-c) steps are performed by a processor of a computing device.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said sample is selected from the group consisting of a whole blood sample, a plasma sample, a serum sample, a sample comprising purified blood cells, a tissue sample, or a urine sample.
